Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 74Breast Neoplasms 70Rectal Neoplasms 51Stomach Neoplasms 45Glioblastoma 45Esophageal Neoplasms 41Colorectal Neoplasms 37Lung Neoplasms 35Brain Neoplasms 35Squamous Cell Carcinoma of Head and Neck 32Pancreatic Neoplasms 31Glioma 27Neoplasms 26Sarcoma 24Neoplasm Metastasis 23Astrocytoma 22Head and Neck Neoplasms 21Carcinoma, Hepatocellular 19Esophageal Squamous Cell Carcinoma 16Colonic Neoplasms 16Recurrence 15Ovarian Neoplasms 15Melanoma 15Gliosarcoma 15Central Nervous System Neoplasms 15Urinary Bladder Neoplasms 13Oligodendroglioma 13Uterine Cervical Neoplasms 12Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 11

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Surgical Procedures, Operative × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡